CM Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

CM Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,000	Closed	-$11K	–	73
2023 Q2	$11K	Hold	6,000	–	–	0.01%	73
2023 Q1	$22K	Sell	6,000 -11,500	-66%	-$53.1K	0.03%	62
2022 Q4	$67K	Sell	17,500 -5,000	-22%	-$25.6K	0.08%	70
2022 Q3	$178K	Buy	22,500 +4,000	+22%	+$66.2K	0.2%	70
2022 Q2	$389K	Buy	18,500 +2,250	+14%	+$52.8K	0.41%	62
2022 Q1	$611K	Buy	16,250 +8,750	+117%	+$302K	0.51%	58
2021 Q4	$422K	Buy	7,500 +3,750	+100%	+$252K	0.32%	77
2021 Q3	$271K	Buy	+3,750	New	+$287K	0.2%	84

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CM Management's NBSE Position: Q3 2023 in Review

CM Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2023, closing a stake of 6,000 shares — an estimated $11K sold.

CM Management first reported a position in NBSE in Q3 2021 and held it in 8 quarters. The position peaked at $611K in Q1 2022. 21 funds tracked by Wall St. Rank hold NBSE as of Q3 2023.

CM Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
CM Management sold 6,000 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $11K.
CM Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
CM Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $611K in Q1 2022.
21 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2023.

Based on CM Management's 13F filing for Q3 2023, filed 7 Nov 2023.